Literature DB >> 6226620

Lymphocyte function in patients with chronic glomerulonephritis. Tests of suppressive activity generation by concanavalin A and antibody-dependent cellular cytotoxicity.

Z Szewczyk, M Klinger, W Kopec, J Penar, E Kruźel.   

Abstract

Lymphocyte suppressive activity after stimulation with Con A and lymphocyte function as the effectors in the ADCC test had been examined in 68 patients with chronic glomerulonephritis (GN) and in 20 healthy controls. Lymphocyte suppressive activity was lower in patients with chronic GN than in the healthy individuals. In regard to chronic proliferative GN and mesangial GN the difference was statistically significant. The lymphocyte efficiency in the ADCC test was generally adequate in patients with chronic GN and none of the morphological types showed significant deviation from the control group. In the general analysis of patients with chronic proliferative, mesangial, membrano-proliferative and membranous GN a decrease of lymphocyte suppressive activity below the lower standard limit has been detected (45% of cases). A similar defect in lymphocyte function in the ADCC test has been found in 18.6%. A statistically significant relationship between the lymphocyte function disorders and the high clinical dynamism of GN has been noticed, although in some cases there was a deviation from this tendency. It is supposed that circulating immune complexes, detected in some patients with chronic GN are not the only decisive factors responsible for defects in lymphocyte function.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6226620     DOI: 10.1007/bf02082111

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  27 in total

Review 1.  In vitro and in vivo investigations on antibody-dependent cellular cytotoxicity.

Authors:  G R Pearson
Journal:  Curr Top Microbiol Immunol       Date:  1978       Impact factor: 4.291

2.  Monocyte-mediated suppression of human B lymphocyte differentiation in vitro.

Authors:  W Knapp; G Baumgartner
Journal:  J Immunol       Date:  1978-09       Impact factor: 5.422

3.  Increase of IgA-bearing lymphocytes in peripheral blood from patients with IgA nephropathy.

Authors:  Y Nomoto; H Sakai; S Arimori
Journal:  Am J Clin Pathol       Date:  1979-02       Impact factor: 2.493

Review 4.  [Functional tests of the immune system].

Authors:  J R Kalden
Journal:  Internist (Berl)       Date:  1979-10       Impact factor: 0.743

5.  Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs.

Authors:  K T Brunner; J Mauel; J C Cerottini; B Chapuis
Journal:  Immunology       Date:  1968-02       Impact factor: 7.397

6.  Separation of leukocytes from blood and bone marrow. Introduction.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

7.  The effects of azathioprine and prednisolone on T- and B-lymphocytes in patients with lupus nephritis and chronic glomerulonephritis.

Authors:  I E Tareyeva; E M Shilov; N B Gordovskaya
Journal:  Clin Nephrol       Date:  1980-11       Impact factor: 0.975

8.  Study of antibody-dependent cellular cytotoxicity (ADCC). I. Lymphocyte-mediated cytotoxicity by lymphocytes from healthy individuals.

Authors:  M Wasik
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  1978       Impact factor: 4.291

9.  Detection of circulating immune complexes in patients with glomerulonephritis.

Authors:  Z Szewczyk; K Falkiewicz; W Kopeć
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  1978       Impact factor: 4.291

10.  Suppressor cell activity after concanavalin A treatment of lymphocytes from normal donors.

Authors:  L Shou; S A Schwartz; R A Good
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

View more
  1 in total

1.  Aldolase and adenosine deaminase activity in lymphocytes of patients with glomerulonephritis.

Authors:  M Klinger; Z Szewczyk; M Robak
Journal:  Int Urol Nephrol       Date:  1983       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.